Shares of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) have been given a consensus recommendation of “Buy” by the five ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $23.00.

JNP has been the topic of several recent analyst reports. ValuEngine upgraded Juniper Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. BMO Capital Markets upgraded Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $31.00 to $34.00 in a report on Friday, July 14th.

TRADEMARK VIOLATION NOTICE: “Juniper Pharmaceuticals, Inc. (JNP) Receives Average Rating of “Buy” from Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/27/juniper-pharmaceuticals-inc-jnp-receives-average-rating-of-buy-from-analysts.html.

Shares of Juniper Pharmaceuticals (NASDAQ JNP) opened at 4.85 on Friday. The stock has a market capitalization of $52.59 million, a P/E ratio of 6.27 and a beta of 0.24. Juniper Pharmaceuticals has a one year low of $3.65 and a one year high of $6.40. The stock’s 50 day moving average is $4.57 and its 200-day moving average is $4.61.

Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The firm had revenue of $13.96 million for the quarter, compared to the consensus estimate of $11.84 million. Juniper Pharmaceuticals had a return on equity of 21.49% and a net margin of 13.94%. On average, equities research analysts expect that Juniper Pharmaceuticals will post ($0.46) EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of JNP. Municipal Employees Retirement System of Michigan acquired a new position in shares of Juniper Pharmaceuticals in the 2nd quarter valued at about $1,192,000. Renaissance Technologies LLC increased its holdings in shares of Juniper Pharmaceuticals by 21.7% in the 1st quarter. Renaissance Technologies LLC now owns 309,500 shares of the specialty pharmaceutical company’s stock valued at $1,470,000 after purchasing an additional 55,200 shares during the period. Nationwide Fund Advisors increased its holdings in shares of Juniper Pharmaceuticals by 5,500.0% in the 2nd quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock valued at $283,000 after purchasing an additional 55,000 shares during the period. JW Asset Management LLC increased its holdings in shares of Juniper Pharmaceuticals by 10.0% in the 2nd quarter. JW Asset Management LLC now owns 426,903 shares of the specialty pharmaceutical company’s stock valued at $2,156,000 after purchasing an additional 38,771 shares during the period. Finally, KCG Holdings Inc. acquired a new position in shares of Juniper Pharmaceuticals in the 1st quarter valued at about $112,000. Institutional investors own 36.20% of the company’s stock.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.